On September 14, 2019 Oncopeptides AB (Nasdaq Stockholm: ONCO) reported that our two poster presentations have been made public at the 17th International Myeloma Workshop (IMW) meeting in Boston, Massachusetts, USA (Press release, Oncopeptides, SEP 14, 2019, View Source [SID1234539499]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The posters presented at IMW
The first poster presentation was held during Poster Session I, Multiple Myeloma Genomics – under the title: Aminopeptidase gene expression in myeloma.

The second poster presentation was held during Poster Session II, Treatment of Previously Treated Myeloma –under the title: Quality of life treatment for relapsed/refractory multiple myeloma, a systematic review.

The posters are available on the company webpage under:
www.oncopeptides.com / Investors&Media / Presentations / IMW 2019

For further information, please contact:
Jakob Lindberg, CEO of Oncopeptides
E-mail: [email protected]
Telephone: +46 8 615 20 40

Rein Piir, Head of Investor Relations at Oncopeptides
E-mail: [email protected]
Cell phone: +46 70 853 72 92

This information was submitted for publication at 13.00 CET September 14, 2019.